CN110743007B - 一种联合疫苗及其制备方法、应用 - Google Patents
一种联合疫苗及其制备方法、应用 Download PDFInfo
- Publication number
- CN110743007B CN110743007B CN201910851923.0A CN201910851923A CN110743007B CN 110743007 B CN110743007 B CN 110743007B CN 201910851923 A CN201910851923 A CN 201910851923A CN 110743007 B CN110743007 B CN 110743007B
- Authority
- CN
- China
- Prior art keywords
- virus
- inactivated
- varicella zoster
- solution
- japanese encephalitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 95
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims abstract description 123
- 241000710842 Japanese encephalitis virus Species 0.000 claims abstract description 107
- 241000700605 Viruses Species 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 34
- 229940001442 combination vaccine Drugs 0.000 claims abstract description 30
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 239000001963 growth medium Substances 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 122
- 210000004027 cell Anatomy 0.000 claims description 66
- 239000007788 liquid Substances 0.000 claims description 47
- 230000002779 inactivation Effects 0.000 claims description 41
- 206010014599 encephalitis Diseases 0.000 claims description 37
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 34
- 229960000380 propiolactone Drugs 0.000 claims description 34
- 210000001840 diploid cell Anatomy 0.000 claims description 33
- 230000000415 inactivating effect Effects 0.000 claims description 33
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 30
- 238000006460 hydrolysis reaction Methods 0.000 claims description 30
- 230000007062 hydrolysis Effects 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 239000012141 concentrate Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000003223 protective agent Substances 0.000 claims description 16
- 239000007853 buffer solution Substances 0.000 claims description 14
- 230000003301 hydrolyzing effect Effects 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 13
- 201000005807 Japanese encephalitis Diseases 0.000 claims description 13
- 238000003306 harvesting Methods 0.000 claims description 13
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 13
- 238000000746 purification Methods 0.000 claims description 11
- 238000000108 ultra-filtration Methods 0.000 claims description 11
- 229930006000 Sucrose Natural products 0.000 claims description 10
- 239000005720 sucrose Substances 0.000 claims description 10
- 208000007514 Herpes zoster Diseases 0.000 claims description 9
- 239000008055 phosphate buffer solution Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000011543 agarose gel Substances 0.000 claims description 3
- 125000000185 sucrose group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 abstract description 4
- 241000894007 species Species 0.000 abstract description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 29
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 17
- 230000002238 attenuated effect Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 13
- 229940031551 inactivated vaccine Drugs 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000003053 immunization Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229940021648 varicella vaccine Drugs 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000003501 vero cell Anatomy 0.000 description 8
- 238000011725 BALB/c mouse Methods 0.000 description 7
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 229940027941 immunoglobulin g Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 4
- 206010052369 Encephalitis lethargica Diseases 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 201000002498 viral encephalitis Diseases 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010074259 Herpes zoster meningitis Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000032370 Secondary transmission Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101900123149 Varicella-zoster virus Envelope glycoprotein E Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000175 potential carcinogenicity Toxicity 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16751—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
成分 | 数量(每剂) |
灭活JEV纯化液 | 0.8mL |
灭活VZV纯化液 | 0.2mL |
氯化钠(NaCl) | 9000μg |
磷酸氢二钠(Na2HPO4) | 1150μg |
磷酸二氢钠(NaH2PO4) | 230μg |
蔗糖 | 20mg |
组别 | 所用药物 | 免疫剂量(/只) |
组别1 | 实施例5所得联合疫苗 | 每次1mL,注射2次 |
组别2 | 实施例6所得联合疫苗 | 每次1mL,注射2次 |
组别3 | 实施例7所得联合疫苗 | 每次1mL,注射2次 |
组别4 | JEV阳性对照 | 每次1mL,注射2次 |
组别5 | VZV阳性对照 | 每次1mL,注射2次 |
组别6 | 阴性对照 | PBS溶液 |
组别 | 所用药物 | 免疫剂量(/只) | 保护率% |
组别1 | 实施例5所得联合疫苗 | 每次1mL,注射4次 | 80 |
组别2 | 实施例6所得联合疫苗 | 每次1mL,注射4次 | 100 |
组别3 | 实施例7所得联合疫苗 | 每次1mL,注射4次 | 100 |
组别4 | JEV阳性对照 | 每次1mL,注射4次 | 100 |
组别5 | 阴性对照 | PBS溶液 | 0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910851923.0A CN110743007B (zh) | 2019-09-10 | 2019-09-10 | 一种联合疫苗及其制备方法、应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910851923.0A CN110743007B (zh) | 2019-09-10 | 2019-09-10 | 一种联合疫苗及其制备方法、应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110743007A CN110743007A (zh) | 2020-02-04 |
CN110743007B true CN110743007B (zh) | 2023-05-30 |
Family
ID=69276247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910851923.0A Active CN110743007B (zh) | 2019-09-10 | 2019-09-10 | 一种联合疫苗及其制备方法、应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110743007B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112143715B (zh) * | 2020-09-29 | 2022-09-30 | 南京启医科技有限公司 | 组合物及其在病毒抑制剂或灭活剂中的应用 |
CN115227811B (zh) * | 2022-08-26 | 2023-07-28 | 上海荣盛生物药业股份有限公司 | 一种水痘-带状疱疹病毒活疫苗原液的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101524536A (zh) * | 2009-03-26 | 2009-09-09 | 成都康华生物制品有限公司 | 人胚肺成纤维细胞乙型脑炎疫苗及其制备方法 |
CN101732707A (zh) * | 2008-11-21 | 2010-06-16 | 上海荣盛生物药业有限公司 | 无汞乙脑灭活疫苗组合物及其应用 |
CN102559617A (zh) * | 2010-12-20 | 2012-07-11 | 北京清大天一科技有限公司 | 生物反应器微载体培养人二倍体细胞生产病毒疫苗的方法 |
WO2017113786A1 (zh) * | 2015-12-31 | 2017-07-06 | 北京大学 | 突变的病毒、其制备方法和应用 |
CN107174658A (zh) * | 2017-04-29 | 2017-09-19 | 安徽智飞龙科马生物制药有限公司 | 人用水痘病毒灭活疫苗及其制备方法 |
CN108992667A (zh) * | 2018-08-09 | 2018-12-14 | 安徽智飞龙科马生物制药有限公司 | 一种带状疱疹疫苗及其制备方法、应用 |
-
2019
- 2019-09-10 CN CN201910851923.0A patent/CN110743007B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732707A (zh) * | 2008-11-21 | 2010-06-16 | 上海荣盛生物药业有限公司 | 无汞乙脑灭活疫苗组合物及其应用 |
CN101524536A (zh) * | 2009-03-26 | 2009-09-09 | 成都康华生物制品有限公司 | 人胚肺成纤维细胞乙型脑炎疫苗及其制备方法 |
CN102559617A (zh) * | 2010-12-20 | 2012-07-11 | 北京清大天一科技有限公司 | 生物反应器微载体培养人二倍体细胞生产病毒疫苗的方法 |
WO2017113786A1 (zh) * | 2015-12-31 | 2017-07-06 | 北京大学 | 突变的病毒、其制备方法和应用 |
CN107174658A (zh) * | 2017-04-29 | 2017-09-19 | 安徽智飞龙科马生物制药有限公司 | 人用水痘病毒灭活疫苗及其制备方法 |
CN108992667A (zh) * | 2018-08-09 | 2018-12-14 | 安徽智飞龙科马生物制药有限公司 | 一种带状疱疹疫苗及其制备方法、应用 |
Non-Patent Citations (1)
Title |
---|
联合接种水痘减毒活疫苗和乙脑减毒活疫苗的可行性分析;陈艳芳;《中国保健营养》;20180119;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN110743007A (zh) | 2020-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2621320C (en) | Vaccines and methods to treat canine influenza | |
TWI579297B (zh) | 用於預防豬病感染之混合疫苗 | |
CN104099301B (zh) | 柯萨奇病毒a16型病毒株、用途、疫苗及其制备方法 | |
JP2000507825A (ja) | 細胞培養におけるインフルエンザウイルスの複製の方法、および本方法によって入手可能なインフルエンザウイルス | |
CN110743007B (zh) | 一种联合疫苗及其制备方法、应用 | |
CN110170048B (zh) | 一种灭活轮状病毒疫苗的制备方法 | |
EP1129723B1 (en) | Combined vaccine against both hav and measle virus and method of producing it | |
CN109689862A (zh) | 重组ev71病毒样颗粒的纯化及其疫苗制备方法 | |
US3526696A (en) | Shipping fever vaccine | |
KR20160018828A (ko) | 불활성화된 바리셀라 조스터 바이러스 백신, 그의 제조 방법 및 용도 | |
CN100513559C (zh) | 新的水痘病毒毒株、水痘减毒活疫苗及其制备方法 | |
CN107174658B (zh) | 人用水痘病毒灭活疫苗及其制备方法 | |
US3585266A (en) | Live rabies virus vaccine and method for the production thereof | |
CN103160475B (zh) | 一种肠道病毒71型病毒株及其用途、疫苗和制备方法 | |
CN112717128B (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
CN112143714B (zh) | 利用低免鸡胚生产h7亚型禽流感病毒灭活疫苗的方法 | |
US3897549A (en) | Herpes simplex type 2 virus vaccine and method of production and use | |
CN103160474B (zh) | 肠道病毒71型病毒株、疫苗、动物模型建立方法 | |
CN116615234A (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
CN109402066B (zh) | 一株7型腺病毒及其制备的疫苗制品 | |
CN1216985C (zh) | 甲型肝炎病毒毒株,制备甲肝灭活疫苗的方法及所得疫苗 | |
JP2007068401A (ja) | 西ナイルウイルスワクチン | |
RU2810740C1 (ru) | Способ получения инактивированной вакцины против covid-19 и вакцина, полученная способом | |
CN112791179B (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
CN109602899B (zh) | 一种增强病毒抗原免疫原性的皮内注射技术及其在手足口病疫苗研究中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 230000, No. 5008 Mingzhu Avenue, Hefei City, Anhui Province Patentee after: ANHUI ZHIFEI LONGCOM BIOPHARMACEUTICAL Co.,Ltd. Patentee after: CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD. Patentee after: BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL Co.,Ltd. Address before: 230088 No.100 Fushan Road, high tech Zone, Hefei City, Anhui Province Patentee before: ANHUI ZHIFEI LONGCOM BIOPHARMACEUTICAL Co.,Ltd. Patentee before: CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD. Patentee before: BEIJING ZHIFEI LVZHU BIOPHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |